Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study

Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N.

2021
Japanese journal of ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Ophthalmology, University of Tokyo, Tokyo, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA. Fenghe.Lu@santen.com; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA

Related Publications

Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma

Kashiwagi K., Nakano T., Nakazawa T., Fuwa M., Otsuka N., Shii D., Miyahara R.

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.

View all Glaucoma publications